Company Overview and News

5
Cryptocurrencies And Blockchain: Longs, Shorts Or Trading Sardines

2017-09-25 seekingalpha
Over the last few months, I slowly added lines here and there to this post in my head. Well, the original: It soon evolved into a bear of a cryptocurrency and blockchain primer. One which, anticipating an eventual audience, kept dragging me down an endless rabbit-hole of what about and what if questions…

 
Atlassian's Mike Cannon-Brookes lays claim to a bitcoin windfall

2017-05-01 theage.com.au
While the billionaire co-founder of Atlassian, Scott Farquhar, was making headlines with the purchase of of Australia's most expensive house - the $70 million Point Piper estate Elaine - his business partner, Mike Cannon-Brookes, found something to crow about in another tech punt that has apparently proved a winner. 

 
Atlassian's Mike Cannon-Brookes lays claim to a bitcoin windfall

2017-05-01 smh.com.au
While the billionaire co-founder of Atlassian, Scott Farquhar, was making headlines with the purchase of of Australia's most expensive house - the $70 million Point Piper estate Elaine - his business partner, Mike Cannon-Brookes, found something to crow about in another tech punt that has apparently proved a winner. 

 
Bitcoin worth more than gold as price reaches all-time high

2017-02-24 theage.com.au
The crypto currency known for its anonymity and decentralised nature reached an all-time high on Friday afternoon, making it more valuable than gold in Australia.

 
Bitcoin worth more than gold as price reaches all-time high

2017-02-24 smh.com.au
The crypto currency known for its anonymity and decentralised nature reached an all-time high on Friday afternoon, making it more valuable than gold in Australia.

 
Automated traders take over bitcoin as easy money beckons

2017-01-17 smh.com.au
Zhou Shuoji is not a bitcoin believer. He says the cryptocurrency will never replace its traditional forebears, and he calls most of its proponents fanatics.

 
Fintech funds are drying up, but some local players welcome the drought

2016-01-26 smh.com.au
The flow of US venture capital to the burgeoning fintech sector is slowing to a drizzle, but surprisingly, some say that's perfectly OK.

 
Close of ASX BookBuild

2016-01-25 asx.com.au

 
Second Replacement Prospectus

2015-12-24 asx.com.au

 
Third Supplementary Prospectus

2015-12-04 asx.com.au

 
Second Supplementary Prospectus

2015-11-20 asx.com.au

 

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...